237 related articles for article (PubMed ID: 37585218)
21. Comprehensive review of statin-intolerance and the practical application of Bempedoic Acid.
Yarrarapu SNS; Goyal A; Venkata VS; Panchal V; Sivasubramanian BP; Du DT; Jakulla RS; Pamulapati H; Afaq MA; Owens S; Dalia T
J Cardiol; 2024 Jul; 84(1):22-29. PubMed ID: 38521120
[TBL] [Abstract][Full Text] [Related]
22. Bempedoic Acid in the Treatment of Patients with Dyslipidemias and Statin Intolerance.
Susekov AV; Korol LA; Watts GF
Cardiovasc Drugs Ther; 2021 Aug; 35(4):841-852. PubMed ID: 33502687
[TBL] [Abstract][Full Text] [Related]
23. Bempedoic acid: Review of a novel therapy in lipid management.
Delevry D; Gupta EK
Am J Health Syst Pharm; 2021 Jan; 78(2):95-104. PubMed ID: 33399194
[TBL] [Abstract][Full Text] [Related]
24. ETC-1002 (Bempedoic acid) for the management of hyperlipidemia: from preclinical studies to phase 3 trials.
Ruscica M; Banach M; Sahebkar A; Corsini A; Sirtori CR
Expert Opin Pharmacother; 2019 May; 20(7):791-803. PubMed ID: 30810432
[TBL] [Abstract][Full Text] [Related]
25. The multifaceted therapeutic value of targeting ATP-citrate lyase in atherosclerosis.
Verberk SGS; Kuiper KL; Lauterbach MA; Latz E; Van den Bossche J
Trends Mol Med; 2021 Dec; 27(12):1095-1105. PubMed ID: 34635427
[TBL] [Abstract][Full Text] [Related]
26. Mendelian Randomization Study of
Ference BA; Ray KK; Catapano AL; Ference TB; Burgess S; Neff DR; Oliver-Williams C; Wood AM; Butterworth AS; Di Angelantonio E; Danesh J; Kastelein JJP; Nicholls SJ
N Engl J Med; 2019 Mar; 380(11):1033-1042. PubMed ID: 30865797
[TBL] [Abstract][Full Text] [Related]
27. Bempedoic Acid's Use as an Adjunct in Lowering Low-Density Lipoprotein Cholesterol in Patients With Coronary Artery Disease: A Systematic Review.
Goit R; Saddik SE; Dawood SN; Rabih AM; Niaj A; Raman A; Uprety M; Calero MJ; Villanueva MRB; Joshaghani N; Villa N; Badla O; Khan S
Cureus; 2022 Oct; 14(10):e29891. PubMed ID: 36348882
[TBL] [Abstract][Full Text] [Related]
28. Bempedoic acid safety analysis: Pooled data from four phase 3 clinical trials.
Bays HE; Banach M; Catapano AL; Duell PB; Gotto AM; Laufs U; Leiter LA; Mancini GBJ; Ray KK; Bloedon LT; Sasiela WJ; Ye Z; Ballantyne CM
J Clin Lipidol; 2020; 14(5):649-659.e6. PubMed ID: 32980290
[TBL] [Abstract][Full Text] [Related]
29. Liver-specific ATP-citrate lyase inhibition by bempedoic acid decreases LDL-C and attenuates atherosclerosis.
Pinkosky SL; Newton RS; Day EA; Ford RJ; Lhotak S; Austin RC; Birch CM; Smith BK; Filippov S; Groot PHE; Steinberg GR; Lalwani ND
Nat Commun; 2016 Nov; 7():13457. PubMed ID: 27892461
[TBL] [Abstract][Full Text] [Related]
30. Factors Associated With Enhanced Low-Density Lipoprotein Cholesterol Lowering With Bempedoic Acid.
Ballantyne CM; Bays HE; Louie MJ; Smart J; Zhang Y; Ray KK
J Am Heart Assoc; 2022 Aug; 11(15):e024531. PubMed ID: 35916348
[TBL] [Abstract][Full Text] [Related]
31. Lowering Targeted Atherogenic Lipoprotein Cholesterol Goals for Patients at "Extreme" ASCVD Risk.
Rosenblit PD
Curr Diab Rep; 2019 Nov; 19(12):146. PubMed ID: 31754844
[TBL] [Abstract][Full Text] [Related]
32. Efficacy and safety of a novel dual modulator of adenosine triphosphate-citrate lyase and adenosine monophosphate-activated protein kinase in patients with hypercholesterolemia: results of a multicenter, randomized, double-blind, placebo-controlled, parallel-group trial.
Ballantyne CM; Davidson MH; Macdougall DE; Bays HE; Dicarlo LA; Rosenberg NL; Margulies J; Newton RS
J Am Coll Cardiol; 2013 Sep; 62(13):1154-62. PubMed ID: 23770179
[TBL] [Abstract][Full Text] [Related]
33. Bempedoic acid plus ezetimibe fixed-dose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated statin therapy.
Ballantyne CM; Laufs U; Ray KK; Leiter LA; Bays HE; Goldberg AC; Stroes ES; MacDougall D; Zhao X; Catapano AL
Eur J Prev Cardiol; 2020 Apr; 27(6):593-603. PubMed ID: 31357887
[TBL] [Abstract][Full Text] [Related]
34. Bempedoic Acid Unveils Therapeutic Potential in Non-Alcoholic Fatty Liver Disease: Suppression of the Hepatic PXR-SLC13A5/ACLY Signaling Axis.
Sun Q; Guo Y; Hu W; Zhang M; Wang S; Lei Y; Meng H; Li N; Xu P; Li Z; Lin H; Huang F; Qiu Z
Drug Metab Dispos; 2023 Dec; 51(12):1628-1641. PubMed ID: 37684055
[TBL] [Abstract][Full Text] [Related]
35. Lipid lowering with bempedoic acid added to a proprotein convertase subtilisin/kexin type 9 inhibitor therapy: A randomized, controlled trial.
Rubino J; MacDougall DE; Sterling LR; Kelly SE; McKenney JM; Lalwani ND
J Clin Lipidol; 2021; 15(4):593-601. PubMed ID: 34172394
[TBL] [Abstract][Full Text] [Related]
36. Bempedoic Acid: a cholesterol lowering agent with a novel mechanism of action.
Nguyen H; Akamnonu I; Yang T
Expert Rev Clin Pharmacol; 2021 May; 14(5):545-551. PubMed ID: 33691561
[TBL] [Abstract][Full Text] [Related]
37. Inflammation and Cholesterol as Predictors of Cardiovascular Events Among 13 970 Contemporary High-Risk Patients With Statin Intolerance.
Ridker PM; Lei L; Louie MJ; Haddad T; Nicholls SJ; Lincoff AM; Libby P; Nissen SE;
Circulation; 2024 Jan; 149(1):28-35. PubMed ID: 37929602
[TBL] [Abstract][Full Text] [Related]
38. Bempedoic acid as treatment for subjects at cardiovascular risk who are statin-intolerant.
Doggrell SA
Expert Opin Pharmacother; 2023; 24(15):1673-1677. PubMed ID: 37496276
[TBL] [Abstract][Full Text] [Related]
39. Bempedoic acid: a promising novel agent for LDL-C lowering.
Agarwala A; Goldberg AC
Future Cardiol; 2020 Sep; 16(5):361-371. PubMed ID: 32463301
[TBL] [Abstract][Full Text] [Related]
40. Safety of bempedoic acid in patients at high cardiovascular risk and with statin intolerance.
Bays HE; Bloedon LT; Lin G; Powell HA; Louie MJ; Nicholls SJ; Lincoff AM; Nissen SE
J Clin Lipidol; 2024; 18(1):e59-e69. PubMed ID: 37951797
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]